Live COVID-19 Panel

By SDARTs Admin

This event has passed, but the recording is available to view for free on the SDARTs Online Learning Platform >
Potential Use of Adipose-Derived cSVF in Treatment of Post-COVID-19 Lung Damage 

A Live Zoom Panel Discussion and Q&A

October 17, 2020

 

The San Diego Academy of Regenerative Therapies invites you to a complimentary live zoom panel discussion and Q&A on the potential use of adipose-derived cSVF in treatment of post-COVID-19 lung damage
[NCT #04326036 an FDA Oversight Trial]

 

Featuring:

Doctors Robert W. Alexander, Ramon Llull, & T. Scott Stanwyck

Learn how AD-cSVF (Adipose-derived Cellular Stromal Vascular Fraction) can potentially perform as a regenerative COVID patient therapy and how new technology for functional respiratory imaging and lung function can validate the efficacy of the application.
 
Date: Saturday, October 17, 2020
Time: 8:30am PDT

Panel Topics will include: 
  • Patient Physical Impact From SARS-CoV-2 (COVID-19)
  • Overview discussion of Patient Issues
  • Potential of Use of AD-cSVF to help mitigate lung damage in Post-COVID-19 patients
  • Discussion of Functional Respiratory Imaging and Lung Function Testing
  • Scientific data supporting the potential of using Adipose cSVF for mitigating lung damage
  • Materials and Method for harvesting, processing, and administering AD-cSVF
Panelists:
Dr. Robert W. Alexander, MD, DMD, FICS - Principle Investigator
Dr. Ramón Llull, MD, Ph.D.

Moderator: Dr. Scott Stanwyck, MD

Read Dr. Alexander’s breakthrough study: “Overview of COVID-19 Lung Damage Clinical Trial Using Cellular Stromal Vascular Fraction (cSVF) and Functional Respiratory Imaging (FRI) Analysis of Pulmonary Injury & Post-Viral (SARS-CoV-2) Adult Respiratory Distress Syndrome (ARDS),” which was published in Stem Cell Research.

Registration is simple. Click on the link below, fill in the registration form, and we’ll send you a Zoom invite. Be sure to mark your calendar for October 17, 2020, 8:30 am Pacific Time.
Watch the Recording >

Leave a comment